Novo Nordisk presents CagriSema and zenagamtide data at ADA 2026

Novo Nordisk presented phase 3 results for its investigational combination drug CagriSema in type 2 diabetes and phase 2b results for zenagamtide, formerly known as amycretin, at the American Diabetes Association's 2026 Scientific Sessions in New Orleans. The meeting ran June 5–8, 2026, and the CagriSema data were featured in a symposium on Sunday, June 7 ^[1].

What was presented

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. It is given as a once-weekly subcutaneous injection and is being studied in the REIMAGINE program for adults with type 2 diabetes and in the REDEFINE program for adults with overweight or obesity ^[1]. The REIMAGINE 1, 2 and 3 trials tested the drug across a range of background diabetes therapies. The company's announcement did not include the specific A1C or weight-loss numbers from those trials, and the results had not been published in a peer-reviewed journal as of September 2026 ^[1].

Zenagamtide is a single molecule that acts on both GLP-1 and amylin receptors, and it is being developed for injection and for oral use ^[1]. In the phase 2b trial in type 2 diabetes, 448 people whose blood sugar was not adequately controlled on metformin took part, and about 40% were already using an SGLT2 inhibitor ^[2]. At week 36, participants taking a weekly subcutaneous injection had A1C reductions of up to 1.8 percentage points, compared with 0.2 points on placebo. Average A1C was 7.8% at the start. A1C fell below 7% in 89.1% of those participants and to 6.5% or lower in 76.2% ^[2]. A once-daily oral version lowered A1C by up to 1.5 points, versus 0.4 points for placebo, from a starting average of 8%. A1C fell below 7% in 77.6% of those participants and to 6.5% or lower in 62.6% ^[2].

On weight, the subcutaneous group lost up to 14.5% of body weight from a mean starting weight of 99.2 kg by week 36, compared with 2.6% on placebo. Oral zenagamtide produced up to 10.1% weight loss from a mean starting weight of 101.1 kg, compared with 2.5% on placebo ^[2]. Weight loss had not plateaued at week 36 on the higher doses, which the company said suggests patients could lose more in longer trials. Side effects were mostly mild to moderate gastrointestinal events ^[2].

For context, Novo has reported a 2.2% mean A1C change and a 15.6% body weight reduction at 32 weeks in a small phase 2 CagriSema trial, and a phase 3 CagriSema trial showed 13.7% weight loss at week 68, with 73.5% of patients reaching an A1C of 6.5% or less ^[2]. Novo's chief scientific officer has said the company's base case is that zenagamtide will match CagriSema on safety, tolerability and efficacy, and that a single molecule could be easier to manufacture and deliver than a two-drug combination ^[2].

The meeting also included new Ozempic and Wegovy analyses from Novo, covering areas such as blood pressure, kidney outcomes, sleep apnea and cardiovascular risk, among 40 abstracts from the company ^[1].

Why it matters for patients

Neither CagriSema nor zenagamtide is approved in the United States. Their safety and efficacy are not established, and there is no guarantee they will become commercially available for the uses under study ^[1]. Nothing reported here changes what is available today: semaglutide is sold as Wegovy injection 2.4 mg, Wegovy HD injection 7.2 mg, Wegovy tablets 25 mg, and Ozempic injection and tablets ^[1].

Both datasets came from adults with type 2 diabetes, many already taking metformin. Conference presentations are not the same as peer-reviewed publication; the REIMAGINE 1–3 and zenagamtide phase 2b results had not appeared in a peer-reviewed journal as of September 2026, so independent review is still pending. The data do not address cost, insurance coverage, or how these drugs would compare head-to-head with currently available options. Those questions have not been reported.

What happens next

• Novo scheduled an R&D investor event on the science presented at the conference for Sunday, June 7, 2026, with a live webcast ^[1].
• Novo has committed to starting phase 3 development of zenagamtide, then called amycretin, in type 2 diabetes in 2026 ^[2].
• Peer-reviewed publication of the REIMAGINE 1–3 and zenagamtide phase 2b results had not been reported as of September 2026.